

# **Product datasheet for TL313485V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **DHCR7 Human shRNA Lentiviral Particle (Locus ID 1717)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** DHCR7 Human shRNA Lentiviral Particle (Locus ID 1717)

Locus ID: 1717 Synonyms: SLOS

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** DHCR7 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001163817, NM 001360, NM 001360.1, NM 001360.2, NM 001163817.1, BC000054,

NM 001360.3

UniProt ID: Q9UBM7

Summary: This gene encodes an enzyme that removes the C(7-8) double bond in the B ring of sterols

and catalyzes the conversion of 7-dehydrocholesterol to cholesterol. This gene is ubiquitously expressed and its transmembrane protein localizes to the endoplasmic reticulum membrane and nuclear outer membrane. Mutations in this gene cause Smith-Lemli-Opitz syndrome (SLOS); a syndrome that is metabolically characterized by reduced serum cholesterol levels and elevated serum 7-dehydrocholesterol levels and phenotypically characterized by cognitive disability, facial dysmorphism, syndactyly of second and third toes, and holoprosencephaly in severe cases to minimal physical abnormalities and near-normal intelligence in mild cases. Alternative splicing results in multiple transcript variants that

encode the same protein.[provided by RefSeq, Aug 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.






### Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.


For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

## **Product images:**




GFP signal was observed under microscope at 48 hours after transduction of TL313485A virus into HEK293 cells. TL313485A virus was prepared using lenti-shRNA TL313485A and [TR30037] packaging kit.






GFP signal was observed under microscope at 48 hours after transduction of TL313485B virus into HEK293 cells. TL313485B virus was prepared using lenti-shRNA TL313485B and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL313485C] virus into HEK293 cells. [TL313485C] virus was prepared using lenti-shRNA [TL313485C] and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL313485D] virus into HEK293 cells. [TL313485D] virus was prepared using lenti-shRNA [TL313485D] and [TR30037] packaging kit.